Trends in the Ready To Use Blood Cancer Diagnostics Market 2018-2020

Increase in the prevalence of oncological diseases and technological advancements in diagnostics are positively impacting the global blood cancer diagnostics market. Focus on detecting cancer at an early stage through molecular and RNA/DNA testing can widely improve the diagnosis. As spending on healthcare witnesses a gradual increase in developing countries, the overall blood cancer diagnostics market is projected to grow at a steady rate during the forecast period 2017-2022. According to Fact.MR’s analysis, the global blood cancer diagnostics market is projected to grow at a steady CAGR during the forecast period.

Fact.MR’s report offers market analysis and forecast on the global blood cancer diagnostics market on the basis of test type. Liquid biopsy is another test type that remains widely used among end-users. Studies have shown that liquid biopsy can overcome challenges related to intra- and inter-tumor heterogeneity. The research was carried out at Harvard Medical School and Massachusetts General Hospital Cancer Center. Inclusion of liquid biopsy can help in identifying resistance alternations in patients with advanced cholangiocarcinoma. On account of growing preference for liquid biopsy, this segment is projected to increase at a CAGR of over 10% through 2022.

Request Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=47

According to the report, the CBC test segment type of the global blood cancer market is valued at nearly US$ 77 million in 2017. By 2022, this is projected to grow at a healthy rate. The market in North America will remain lucrative for manufacturers throughout the forecast period. The CTC tests segment on the other hand, is anticipated to grow at a relatively higher CAGR than the CBC test segments.

Owing to accuracy and convenience of blood testing protein test type, it is anticipated that more end-use sectors will continue to use this type of testing globally. Fact.MR estimates the global blood protein testing market to rake in significant revenues during the forecast period.

By end-users, hospital associated labs account for a significant percentage of the global blood cancer diagnostics market. Valued at over US$ 136 million in 2017, the hospital associated labs segment is projected to surpass US$ 180 million in revenues by 2022. Demand from hospital associated labs segment is projected to grow at a steady CAGR during the forecast period.

Request/View Toc@ https://www.factmr.com/connectus/sample?flag=T&rep_id=47

Competition Tracking

The key companies profiled in Fact.MR’s research include Abbott Laboratories, Roche Holding A.G., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Luminex Corporation, Myriad Genetics Inc., NanoString Technologies Inc, NeoGenomics Laboratories, Inc., Siemens AG, Quest Diagnostics Incorporated, Qiagen N.V., Agilent Technologies, Biotheranostics, Inc, Almac Group Limited, and GeneNews Limited.

Overall, the global blood cancer diagnostics market is anticipated to witness steady growth through 2022. The market will continue to be influenced by regulatory policies and guidelines.

Table of Contents Covered in the report are:

Chapter 1. Global Blood Cancer Diagnostics Market - Executive Summary. 12

Chapter 2. Global Blood Cancer Diagnostics Market Overview. 14
2.1. Introduction. 14
2.1.1. Global Blood Cancer Diagnostics Market Taxonomy. 14
2.1.2. Global Blood Cancer Diagnostics Market Definition. 14
2.2. Global Blood Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 15
2.2.1. Global Blood Cancer Diagnostics Market Y-o-Y Growth. 15
2.3. Global Blood Cancer Diagnostics Market Dynamics. 15
2.3.1. Drivers. 15
2.3.2. Restraints. 16
2.3.3. Trends. 16
2.4. Supply Chain. 16
2.5. Epidemiology. 16
2.6. List of Distributors. 16
2.7. Average Pricing Analysis. 17
2.8. Regulations. 17
2.9. Key Participants Market Presence (Intensity Map) By Region. 17

Speak To Research Analyst for Detailed Insights @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=47

Chapter 3. Global Blood Cancer Diagnostics Market Analysis and Forecast By Test Type. 18
3.1. Global Blood Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022. 18
3.1.1. CBC Tests Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 18
3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 18
3.1.1.2. Market Share Comparison, By Region. 20
3.1.1.3. Y-o-Y growth Comparison, By Region. 20
3.1.2. CTC Tests Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 21
3.1.2.1. Revenue (US$ Mn) Comparison, By Region. 21
3.1.2.2. Market Share Comparison, By Region. 23
3.1.2.3. Y-o-Y growth Comparison, By Region. 23
3.1.3. Blood Protein Testing Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 24
3.1.3.1. Revenue (US$ Mn) Comparison, By Region. 24
3.1.3.2. Market Share Comparison, By Region. 26
3.1.3.3. Y-o-Y growth Comparison, By Region. 26
3.1.4. Liquid Biopsy Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 27
3.1.4.1. Revenue (US$ Mn) Comparison, By Region. 27
3.1.4.2. Market Share Comparison, By Region. 29
3.1.4.3. Y-o-Y growth Comparison, By Region. 29
3.1.5. Bone Marrow Biopsy Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 30
3.1.5.1. Revenue (US$ Mn) Comparison, By Region. 30
3.1.5.2. Market Share Comparison, By Region. 32
3.1.5.3. Y-o-Y growth Comparison, By Region. 32
3.1.6. Others Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 33
3.1.6.1. Revenue (US$ Mn) Comparison, By Region. 33
3.1.6.2. Market Share Comparison, By Region. 35
3.1.6.3. Y-o-Y growth Comparison, By Region. 35

Access This Report @ https://www.factmr.com/checkout/47/S

Chapter 4. Global Blood Cancer Diagnostics Market Analysis and Forecast By End User. 37
4.1. Global Blood Cancer Diagnostics Market Size and Forecast By End User, 2012-2022. 37
4.1.1. Hospital Associated Labs Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 37
4.1.1.1. Revenue (US$ Mn) Comparison, By Region. 37
4.1.1.2. Market Share Comparison, By Region. 39
4.1.1.3. Y-o-Y growth Comparison, By Region. 39
4.1.2. Independent Diagnostic Laboratories Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 40
4.1.2.1. Revenue (US$ Mn) Comparison, By Region. 40
4.1.2.2. Market Share Comparison, By Region. 42
4.1.2.3. Y-o-Y growth Comparison, By Region. 42
4.1.3. Cancer Research Institutes Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 43
4.1.3.1. Revenue (US$ Mn) Comparison, By Region. 43
4.1.3.2. Market Share Comparison, By Region. 45
4.1.3.3. Y-o-Y growth Comparison, By Region. 45
4.1.4. Others Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 46
4.1.4.1. Revenue (US$ Mn) Comparison, By Region. 46
4.1.4.2. Market Share Comparison, By Region. 48
4.1.4.3. Y-o-Y growth Comparison, By Region. 48

Chapter 5. Global Blood Cancer Diagnostics Market Analysis and Forecast By Region. 50
5.1. Global Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 50
5.1.1. North America Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 50
5.1.1.1. Revenue (US$ Mn) Comparison, By Test Type. 50
5.1.1.2. Revenue (US$ Mn) Comparison, By End User. 52
5.1.2. Latin America Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 54
5.1.2.1. Revenue (US$ Mn) Comparison, By Test Type. 54
5.1.2.2. Revenue (US$ Mn) Comparison, By End User. 55
5.1.3. Europe Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 57
5.1.3.1. Revenue (US$ Mn) Comparison, By Test Type. 57
5.1.3.2. Revenue (US$ Mn) Comparison, By End User. 59
5.1.4. Japan Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 61
5.1.4.1. Revenue (US$ Mn) Comparison, By Test Type. 61
5.1.4.2. Revenue (US$ Mn) Comparison, By End User. 62
5.1.5. APEJ Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 64
5.1.5.1. Revenue (US$ Mn) Comparison, By Test Type. 64
5.1.5.2. Revenue (US$ Mn) Comparison, By End User. 66
5.1.6. MEA Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 67
5.1.6.1. Revenue (US$ Mn) Comparison, By Test Type. 67
5.1.6.2. Revenue (US$ Mn) Comparison, By End User. 69

Chapter 6. North America Blood Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 71
6.1. US Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 71
6.1.1. Revenue (US$ Mn) Comparison, By Test Type. 71
6.1.2. Revenue (US$ Mn) Comparison, By End User. 72
6.2. Canada Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 73
6.2.1. Revenue (US$ Mn) Comparison, By Test Type. 73
6.2.2. Revenue (US$ Mn) Comparison, By End User. 74

Chapter 7. Latin America Blood Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 75
7.1. Brazil Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 75
7.1.1. Revenue (US$ Mn) Comparison, By Test Type. 75
7.1.2. Revenue (US$ Mn) Comparison, By End User. 76
7.2. Mexico Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 77
7.2.1. Revenue (US$ Mn) Comparison, By Test Type. 77
7.2.2. Revenue (US$ Mn) Comparison, By End User. 78
7.3. Argentina Blood Cancer Diagnostics Market Size and Forecast, 2012-2022. 79
7.3.1. Revenue (US$ Mn) Comparison, By Test Type. 79
7.3.2. Revenue (US$ Mn) Comparison, By End User. 80

And Continue...

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: www.factmr.com/
Follow Us on Linkedin: www.linkedin.com/company/factmr/

This release was published on openPR.